Avigen Logo
About Avigen Research & Development Pipeline Clinical Trials Investors Contact Us
 

Andrew A. Sauter is Chief Financial Officer and Acting President and CEO. Mr. Sauter was appointed Chief Financial Officer in February 2008, after having served as Vice President, Finance since January 2006. Mr. Sauter joined Avigen as Controller in November 1999. Mr. Sauter oversees the financial reporting obligations of Avigen and its information technology needs. From 1992 to 1999, Mr. Sauter worked for BankAmerica Corporation in a variety of positions, including most recently as a Vice President in the Capital Markets Finance organization. From 1989 to 1992, he worked for Ernst & Young LLP. Mr. Sauter is a certified public accountant and holds a B.A. degree in economics from Claremont McKenna College.

Kirk W. Johnson, Ph.D., is Vice President, Research and Development. Prior to joining Avigen in early 2004, he was senior director, pharmacology and preclinical development and a member of the executive management team of Genesoft Pharmaceuticals. From 1991 through 2001, Dr. Johnson was employed in both protein and small molecule therapeutic R&D at Chiron Corporation and eventually served as director, pharmacology and preclinical research. Dr. Johnson was involved in creating IND-enabling programs and contributing to successful IND and NDA filings at Chiron and Genesoft. Aside from general pharmacology and other preclinical development responsibilities, he has led research and clinical development projects for diverse indications including neuropathic pain, hemophilia, antibacterials, diabetes, obesity, acute inflammation, and cardiovascular disease. Dr. Johnson earned a B.S. in toxicology from the University of California, Davis, and a Ph.D. in pharmacology and toxicology from the Medical College of Virginia. He did postdoctoral fellowships studying the mechanism of action of IL-2 from 1986 to1989 with Dr. Kendall Smith at Dartmouth and from 1990 to 1991 with Dr. Marian Koshland at the University of California, Berkeley. He has published 60 manuscripts and has several issued U.S. patents.